ABC | Volume 112, Nº1, Janeiro 2019

Artigo Original Quintella et al ICP guiada por FFR x angiografia na doença multivascular Arq Bras Cardiol. 2019; 112(1):40-47 1. Hachamovitch R, Rozanski A, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012-24. 2. Aarnoudse WH, Botman KJ, Pijls NH. False-negative myocardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement. Int J Cardiovasc Intervent. 2003;5(2):67-71. 3. Fischer JJ, Samady H, McPherson JA, Sarembock IJ, Gimple LW, et al. Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. Am J Cardiol. 2002;90(3):210-5. 4. De Bruyne B, FearonWF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208-17. Erratum in: N Engl J Med. 2014;371(15):1465. 5. Sant’Anna FM, Silva ER, Batista LA, BritoMB et al. Qual o erro da angiografia na definição de isquemia miocárdica durante intervenções coronarianas percutâneas? Arq Bras Cardiol. 2008;91(3):179-84. 6. Pijls NH. Optimum guidance of complex PCI by coronary pressure measurement. Heart. 2004;90(9):1085-93. 7. Sant’Anna FM, Silva EE, Batista LA, Ventura FM, Barrozo CA, Pijls NH. Influence of routine assessment of fractional flow reserve on decisionmaking during coronary interventions. Am J Cardiol. 2007;99(4):504-8. 8. Pijls NH, van Schaardenburgh P, Boersma E, Bech JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-yearfollow-upoftheDEFERStudy.JAmCollCardiol.2007;49(21):2105-11. 9. FearonWF, Yeung AC, Lee DP, Yock PG, Heidenreich PA. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions. Am Heart J. 2003;145(5):882-7. 10. Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus- eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol. 2007;88(4):464-74. 11. HachamovitchR,KangX,AmanullahAM,AbidovA,HayesSW,Friedman JD, etal.Prognostic implicationsofmyocardialperfusionsingle-photonemission computed tomography in the elderly. Circulation. 2009;120(22):2197-206. 12. ShawLJ, BermanDS,MaronDJ, Hartigan PM, et al; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and AggressiveDrug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283-91. 13. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches. Executive summary of the ISCHEMIA trial 2013. [on-line]. [cited 2016 Jun 14]. Available from: <http://www.docsrush. net/2451891/executive-summary-of-the-ischemia-trial-february 2013.html 14. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Relatório de Recomendação da Comissão Nacional de Incorporação de Tecnologias no SUS – CONITEC – 111. Stent farmacológico para o tratamento da DAC. [on-line]. 2014. [acesso em 2016 jul. 25]. Disponível em: <http://u.saude.gov.br/images/pdf/2014/marco/17/ StentFarmacologicoCP-111.pdf> 15. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study: fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816-21 16. Bravata DM, Gienger AL, McDonald KM, SundaramV, Perez MV, Varghese R, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med. 2007;147:703-16. 17. Li J, Elrashidi MY, Flammer AJ, Lennon RJ, Bell MR, Holmes DR,et al. Longterm outcomes of fractional flow reserve-guided vs. angiography- guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34(18):1375-83. 18. De Backer O, Biasco L, Lønborg J, Pedersen F, Holmvang L, Kelbaek H, et al. Long-termoutcome of FFR-guided PCI for stable coronary artery disease in daily clinical practice: a propensity score-matched landmark analysis EuroIntervention. 2016;11(11):e1257-66. 19. Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, et al; Investigators of the Registre Français de la FFR–R3F. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129(2):173-85. 20. Zhang D, Lv S, Song X, Yuan F, Xu F, Zhang M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention: a metaanalysis. Heart. 2015;101(6):455-62. 21. MoreiraPBB.Custo-efetividadedeprogramasdereabilitaçãocardiovascular. Jornal do Departamento de Ergometria e Reabilitação Cardíaca. 2004;27:14-6. 22. Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, et al; Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators. Economic evaluation of fractional flow reserveguided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545-50. 23. Teich V, Araújo DV. Estimativa de custo da síndrome coronariana aguda no Brasil. Rev Bras Cardiol. 2011;24(2):85-94. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 47